- Home
- COHN vs KZIA Comparison
COHN vs KZIA Comparison
Compare COHN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COHN
- KZIA
- Stock Information
- Founded
- COHN 1999
- KZIA 1994
- Country
- COHN United States
- KZIA Australia
- Employees
- COHN N/A
- KZIA N/A
- Industry
- COHN Investment Bankers/Brokers/Service
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- COHN Finance
- KZIA Health Care
- Exchange
- COHN Nasdaq
- KZIA Nasdaq
- Market Cap
- COHN 20.2M
- KZIA 18.7M
- IPO Year
- COHN N/A
- KZIA 1999
- Fundamental
- Price
- COHN $10.18
- KZIA $1.69
- Analyst Decision
- COHN
- KZIA Strong Buy
- Analyst Count
- COHN 0
- KZIA 1
- Target Price
- COHN N/A
- KZIA $20.00
- AVG Volume (30 Days)
- COHN 6.5K
- KZIA 124.0K
- Earning Date
- COHN 03-05-2025
- KZIA 01-17-2025
- Dividend Yield
- COHN 9.73%
- KZIA N/A
- EPS Growth
- COHN N/A
- KZIA N/A
- EPS
- COHN 2.35
- KZIA N/A
- Revenue
- COHN $89,555,000.00
- KZIA $1,655,324.00
- Revenue This Year
- COHN N/A
- KZIA $806.89
- Revenue Next Year
- COHN N/A
- KZIA N/A
- P/E Ratio
- COHN $4.38
- KZIA N/A
- Revenue Growth
- COHN 63.18
- KZIA 248000.00
- 52 Week Low
- COHN $6.10
- KZIA $1.67
- 52 Week High
- COHN $12.82
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- COHN 46.83
- KZIA 22.33
- Support Level
- COHN $10.13
- KZIA $1.68
- Resistance Level
- COHN $10.65
- KZIA $1.89
- Average True Range (ATR)
- COHN 0.44
- KZIA 0.31
- MACD
- COHN -0.07
- KZIA -0.07
- Stochastic Oscillator
- COHN 45.83
- KZIA 2.89
About COHN Cohen & Company Inc.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.